Trials / Completed
CompletedNCT00038077
Reversal of Ventricular Remodeling With Toprol-XL
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Seloken ZOK/Toprol-XL | 50 mg |
| DRUG | Seloken ZOK/Toprol-XL | 200 mg |
| DRUG | Placebo |
Timeline
- Start date
- 2001-08-01
- Primary completion
- 2003-09-01
- Completion
- 2003-09-01
- First posted
- 2002-05-29
- Last updated
- 2010-11-19
Locations
44 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00038077. Inclusion in this directory is not an endorsement.